Drug regulators are weighting the merits of disclosing preliminary results from experiments to justify a drug's federal approval and then monitor its safety



-- Read more on ScientificAmerican.com




Source: FDA Debates Secrecy Surrounding Experimental Drugs


David Cottle

UBB Owner & Administrator